

## ANNEX II

### PART B

#### **Criteria establishing the safety of GMMs for human health and the environment**

This Annex describes in general terms the criteria to be met when establishing the safety of types of GMMs for human health and the environment and their suitability for inclusion in Part C. Technical guidance notes may be developed in accordance with the regulatory procedure referred to in Article 20(3) in order to facilitate the implementation and explanation of this Annex.

#### **1. Introduction**

Types of GMMs listed in Part C in accordance with the regulatory procedure with scrutiny referred to in Article 20(2) are excluded from the scope of this Directive. GMMs will be added to the list on a case-by-case basis and exclusion will relate only to each clearly identified GMM. This exclusion applies only when the GMM is used under conditions of contained use as defined in point (c) of Article 2. It does not apply to the deliberate release of GMMs. For a GMM to be listed in Part C, it must be proved that it meets the criteria given below.

#### **2. General criteria**

##### **2.1. Strain verification/authentication**

Identity of the strain must be precisely established. Modification must be known and verified.

##### **2.2. Documented and established evidence of safety**

Documented evidence of the safety of the organism must be provided.

##### **2.3. Genetic stability**

Where any instability could adversely affect safety, evidence of stability is required.

#### **3. Specific criteria**

##### **3.1. Non-pathogenic**

The GMM should not be capable of causing disease or harm to a healthy human, plant or animal. Since pathogenicity includes both toxigenicity and allergenicity, the GMM should therefore be:

###### **3.1.1. Non-toxigenic**

The GMM should not produce increased toxigenicity as a result of the genetic modification nor be noted for its toxigenic properties.

###### **3.1.2. Non-allergenic**

The GMM should not produce increased allergenicity as a result of the genetic modification nor be a noted allergen, having, for example, allergenicity comparable in particular with that of the micro-organisms identified in Directive 2000/54/EC.

##### **3.2. No harmful adventitious agents**

The GMM should not harbour known harmful adventitious agents such as other micro-organisms, active or latent, existing alongside or inside the GMM, that could cause harm to human health and the environment.

---

*Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

---

### 3.3. Transfer of genetic material

The modified genetic material must not give rise to harm if transferred; nor should it be self-transmissible or transferable at a frequency greater than other genes of the recipient or parental micro-organism.

### 3.4. Safety for the environment in the event of a significant and unintended release

GMMs must not produce adverse effects on the environment, immediate or delayed, should any incident involving a significant and unintended release occur.

GMMs that do not meet the above criteria may not be included in Part C.